ADJUVANT Study of Gefitinib as Adjuvant Treatment After Lung Cancer Surgery Published in The LANCET Oncology
On November 21, The LANCET Oncology (IF 33.9), the world’s top journal on oncology, published online the full text of ADJUVANT study of gefitibib as adjuvant treatment after lung cancer surgery. The study shows that adjuvant gefitinib could be a potential treatment option for non-small-cell lung cancer (NSCLC) patients.
This ADJUVANT study was led by Professor Wu Yilong from Guangdong Provincial People’s Hospital, with twenty-seven centers participation from across the country. It was an eight-year randomized control study. Li Jian, Director of the Thoracic Surgery Department of Peking University First Hospital, and Doctor Huang Wei took part in the study. It initiated the adjuvant epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment for NSCLC, and proved for the first time that patients with completely resected EGFR-mutant stage II-IIIA (N1-N2) NSCLC significantly benefited from the adjuvant EGFR-TKI treatment, with a two-year disease-free survival.
Li Jian, Director of the Thoracic Surgery Department of Peking University First Hospital
Doctor Team of Thoracic Surgery Department
Written by: Lang Lang
Edited by: Liu Xin
Source: Peking University First Hospital